Sök artiklar i SveMed+

Tidskrift

Sammanfattning

Biological agents such as tumor necrosis factor-alpha blockers have contributed to a significant improvement in the care and treatment for patients with rheumatic diseases. This applies particularly to the inflammatory joint diseases: rheumatoid arthritis, spondyloarthritis and psoriatic arthritis. Biological drugs are widely used in Norway, and we now have a considerable spectrum of agents to choose from, all with their particular characteristics. Biosimilars have contributed to lowering the price of these expensive medicines, making them more widely available. Rheumatologists in Norway have specific routines for screening patients prior to starting biological agents, and also specific routines for follow-up as patients use these potent immuno-modulators. This article describes how biological drugs are currently being used in treating adult Norwegian rheumatic patients, outlining the relevant guidelines and options applicable.

MeSH